Insufficient p65 phosphorylation at S536 specifically contributes to the lack of NF-kappaB activation and transformation in resistant JB6 cells

Carcinogenesis. 2004 Oct;25(10):1991-2003. doi: 10.1093/carcin/bgh198. Epub 2004 Jun 10.

Abstract

NF-kappaB activation is required for TNF-alpha-induced transformation of JB6 mouse epidermal cells. Deficient activation of p65 contributes to the lack of NF-kappaB activation in transformation-resistant (P-) cells. We hypothesized that the differential NF-kappaB activation involves differential p65 phosphorylation arising from enzyme activity differences. Here we show that TNF-alpha induces greater ERK-dependent p65 phosphorylation at S536 in transformation sensitive (P+) cells than in P- cells. Our results establish that limited ERK content contributes to a low IkappaB kinase (IKKbeta) level, in turn resulting in insufficient p65 phosphorylation at S536 upon TNF-alpha stimulation in P- cells. Phosphorylation of p65 at S536 appears to play a role in TNF-alpha-induced p65 DNA binding and recruitment of p300 to the p65 complex as well as in release of p65 bound to HDAC1 and 3. Blocking p65 phosphorylation at S536, but not at S276 or S529, abolishes p65 transactivational activity. Over-expression of p65 but not p65 phosphorylation mutant (S536A) in transformation-resistant P- cells renders these cells sensitive to TNF-alpha-induced transformation. Over-expression of p65 phosphorylation mimics p65-S536D or p65-S536E in P- cells and also rescues the transformation response. These findings provide direct evidence that phosphorylation of p65 at S536 is required for TNF-alpha-induced NF-kappaB activation in the JB6 transformation model. The lack of NF-kappaB activation seen in P- cells can be attributed to an insufficient level of p65 phosphorylation on S536 that arises from insufficient IKKbeta that in turn arises from insufficient ERK. Thus, p65 phosphorylation at S536 offers a potential molecular target for cancer prevention.

MeSH terms

  • Active Transport, Cell Nucleus
  • Animals
  • Carcinogens / pharmacology
  • Carrier Proteins / metabolism*
  • Cell Adhesion
  • Cell Nucleus / metabolism
  • Cell Transformation, Neoplastic / metabolism*
  • DNA / metabolism
  • E1A-Associated p300 Protein
  • Electrophoretic Mobility Shift Assay
  • Enzyme Inhibitors / pharmacology
  • HeLa Cells
  • Histone Deacetylase 1
  • Histone Deacetylases*
  • Humans
  • I-kappa B Kinase
  • Intracellular Signaling Peptides and Proteins
  • Mice
  • Mitogen-Activated Protein Kinase 1 / metabolism
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases / metabolism
  • Mutation / genetics
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / genetics
  • NF-kappa B / metabolism*
  • Neoplasm Proteins / metabolism*
  • Nuclear Proteins / metabolism
  • Phosphorylation
  • Protein Serine-Threonine Kinases / metabolism*
  • Proteins / antagonists & inhibitors
  • Proteins / metabolism
  • Skin / cytology
  • Skin / drug effects
  • Skin / metabolism*
  • Trans-Activators / metabolism
  • Transcription Factor RelA
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Carcinogens
  • Carrier Proteins
  • Enzyme Inhibitors
  • HSAJ2425 protein, human
  • Intracellular Signaling Peptides and Proteins
  • NF-kappa B
  • Neoplasm Proteins
  • Nuclear Proteins
  • Proteins
  • Rela protein, mouse
  • Trans-Activators
  • Transcription Factor RelA
  • Tumor Necrosis Factor-alpha
  • DNA
  • E1A-Associated p300 Protein
  • Ep300 protein, mouse
  • Protein Serine-Threonine Kinases
  • CHUK protein, human
  • Chuk protein, mouse
  • I-kappa B Kinase
  • IKBKB protein, human
  • IKBKE protein, human
  • Ikbkb protein, mouse
  • Ikbke protein, mouse
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases
  • Hdac1 protein, mouse
  • Histone Deacetylase 1
  • Histone Deacetylases